sa58
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2022 (NCT05664919)
Timeline
No events for the selected filters.
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05667714 | N/A | Nov 26, 2022 | Capital Medical University, China National Pharmaceutical Group |
| NCT05664919 | N/A | Oct 30, 2022 | China National Pharmaceutical Group |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China National Pharmaceutical Group | For profit | 2 | 2 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1